Medical Access Program for Patritumab Deruxtecan

NO_LONGER_AVAILABLE

Conditions studied: Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

In brief

The purpose of this Medical Access Program is to provide access to HER3-DXd for eligible patients with NSCLC who, in their treating physician's opinion, have an unmet clinical need which cannot be treated with approved and commercially available drugs and who cannot enter a clinical trial prior to commercial availability.

Key facts

Study ID
NCT06099639
Run by
Daiichi Sankyo
Last updated by the study team
2025-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.